A real world study of safety and efficacy between regorafenib and trifluridine/tipiracil in patients with mCRC refractory to standard therapies in Bulgaria
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jul 2020 New trial record
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer